PTC Therapeutics

Yahoo Finance • 14 days ago

Netflix initiated, Instacart upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Instacart (CART) to... Full story

Yahoo Finance • 23 days ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 23 days ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • last month

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 1... Full story

Yahoo Finance • last month

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics(NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing. What Happened Accordin... Full story

Yahoo Finance • last month

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and sto... Full story

Yahoo Finance • last month

Oversold Conditions For PTC Therapeutics (PTCT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 2 months ago

PTC Therapeutics stock down over 2% on worse-than-expected Q4 results, guidance

Investing.com -- PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch of Sephience™. Shares... Full story

Yahoo Finance • 2 months ago

PTC Therapeutics drops as it pulls Translarna NDA resubmission

[US Food and Drug Administration (FDA)] * PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) is down ~5% in after-hours trading Thursday after announcing it has withdrawn its NDA resubmission of Translarna (ataluren) for non... Full story

Yahoo Finance • 3 months ago

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

[Roll of dollars with sign royalties and keyboard.] designer491 * Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) has acquired from PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) its remaining royalty intere... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 9 a.m. PST/12... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says

PTC Therapeutics (PTCT) investors are expected to remain focused on the Sephience rollout for phenyl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827

* Principal Spectrum Preferred Secs Active ETF (PREF [https://seekingalpha.com/symbol/PREF]) - $0.0827 [https://www.principalam.com/fund/pref]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story

Yahoo Finance • 4 months ago

Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792

* Principal Investment Grade Corporate Active ETF (IG [https://seekingalpha.com/symbol/IG]) - $0.0792 [https://www.principalam.com/us/fund/ig]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics downgraded at RBC as Sephience sales priced in

[Wall Street sign with American flag in the background, symbolizing the financial heart of New York.] * RBC Capital Markets has downgraded PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) to sector perform from outperform,... Full story

Yahoo Finance • 5 months ago

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc (Symbol: PTCT) have crossed above the average analyst 12-month target price of $54.17, changing hands for $55.13/share. When a stock reaches the target an analyst has set, the analyst logi... Full story

Yahoo Finance • 5 months ago

Sandisk Corp. To Replace Interpublic Group Of Companies In S&P 500

(RTTNews) - S&P Dow Jones Indices, a division of S&P Global (SPGI), announced that S&P SmallCap 600 constituent Sandisk Corp. (SNDK) will replace The Interpublic Group of Companies Inc. (IPG) in the S&P 500, and PTC Therapeutics Inc. (PTCT... Full story

Yahoo Finance • 5 months ago

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (... Full story

Yahoo Finance • 5 months ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 5 months ago

PTC Therapeutics narrows 2025 revenue guidance to $750M–$800M as Sephience launch accelerates

Earnings Call Insights: PTC Therapeutics (PTCT) Q3 2025 MANAGEMENT VIEW * CEO Matthew Klein opened the call by highlighting "the initiation of the Sephience global launch in Europe and the United States" and described Sephience as "the... Full story